Skip to content
Triangle logo TriangleGet started
← Prostate Cancer

TREATMENT READING

Prostate Cancer, part 3

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

137 sections
  1. Follow-Up After Treatment
  2. Follow-up after radical prostatectomy
  3. Follow-up after radiation therapy
  4. Follow-up after hormonal therapy
  5. Treatment Option Overview for Prostate Cancer
  6. Watchful Waiting or Active Surveillance/Active Monitoring
  7. Radical Prostatectomy
  8. Radical prostatectomy compared with other treatment options
  9. Complications of radical prostatectomy
  10. Morbidity and mortality associated with radical prostatectomy
  11. Urinary incontinence and impotence
  12. Penile shortening
  13. Inguinal hernia
  14. Fecal incontinence
  15. Radiation Therapy and Radiopharmaceutical Therapy
  16. External-beam radiation therapy (EBRT)
  17. Conventional versus hypofractionated EBRT
  18. Brachytherapy
  19. Radiopharmaceutical therapy
  20. Alpha emitter radiation
  21. Complications of radiation therapy
  22. Reducing complications
  23. Comparison of complications from radiation therapy and from radical prostatectomy
  24. Hormonal Therapy and Its Complications
  25. Abiraterone acetate
  26. Bilateral orchiectomy
  27. Estrogen therapy
  28. Luteinizing hormone-releasing hormone (LH-RH) agonist therapy
  29. Antiandrogen therapy
  30. ADT
  31. Antiadrenal therapy
  32. Cryosurgery
  33. Proton-Beam Therapy
  34. Photodynamic Therapy
  35. Neoadjuvant Hormonal Therapy
  36. Bicalutamide
  37. Treatment of Stage I Prostate Cancer
  38. Overview
  39. Treatment Options for Stage I Prostate Cancer
  40. Watchful waiting or active surveillance/active monitoring
  41. Radical prostatectomy
  42. External-beam radiation therapy (EBRT)
  43. Interstitial implantation of radioisotopes
  44. Photodynamic therapy
  45. Treatment of Stage II Prostate Cancer
  46. Overview
  47. Prostate-specific antigen (PSA) changes as markers of tumor progression
  48. Bisphosphonates and risk of bone metastases
  49. Treatment Options for Stage II Prostate Cancer
  50. Watchful waiting or active surveillance/active monitoring
  51. Radical prostatectomy
  52. External-beam radiation therapy (EBRT) with or without hormonal therapy
  53. Interstitial implantation of radioisotopes
  54. Ultrasound-guided percutaneous cryosurgery
  55. High-intensity focused ultrasound
  56. Proton-beam radiation therapy
  57. Photodynamic therapy
  58. Treatment of Stage III Prostate Cancer
  59. Overview
  60. Treatment Options for Stage III Prostate Cancer
  61. External-beam radiation therapy (EBRT) with or without hormonal therapy
  62. Hormonal manipulations (with or without radiation therapy)
  63. Immediate versus deferred hormonal therapy
  64. Continuous versus intermittent hormonal therapy
  65. Radical prostatectomy with or without EBRT
  66. Watchful waiting or active surveillance/active monitoring
  67. Treatment of Symptoms
  68. Radiation therapy
  69. Hormonal manipulation
  70. Interstitial implantation combined with EBRT
  71. Alternative forms of radiation therapy
  72. Ultrasound-guided percutaneous cryosurgery
  73. Treatment of Stage IV Prostate Cancer
  74. Overview
  75. Treatment Options for Stage IV Prostate Cancer
  76. Hormonal manipulations
  77. Immediate versus deferred hormonal therapy
  78. Luteinizing hormone-releasing hormone (LH-RH) agonists or antiandrogens
  79. Maximal androgen blockade (MAB)
  80. Continuous versus intermittent hormonal therapy
  81. Hormonal manipulations with chemotherapy
  82. Bisphosphonates
  83. Bisphosphonates and decreasing risk of bone metastases
  84. External-beam radiation therapy (EBRT) with or without hormonal therapy
  85. Palliative radiation therapy
  86. Palliative surgery with transurethral resection of the prostate (TURP)
  87. Watchful waiting or active surveillance/active monitoring
  88. Radical prostatectomy with immediate orchiectomy
  89. Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer
  90. Overview
  91. Immediate Versus Deferred Hormonal Therapy
  92. Hormonal Therapy for Recurring Disease
  93. Continuous versus intermittent hormonal therapy
  94. Nonsteroidal antiandrogen therapy with or without androgen deprivation therapy
  95. Nonsteroidal antiandrogen monotherapy versus surgical or medical castration
  96. Hormonal approaches
  97. Prevention of bone metastases
  98. Treatment Options for Recurrent Prostate Cancer
  99. Chemotherapy for hormone-sensitive or hormone-resistant prostate cancer
  100. Immunotherapy
  101. Radiopharmaceutical therapy
  102. Alpha emitter radiation therapy
  103. Beta emitter radiation therapy
  104. PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants
  105. Olaparib
  106. Hormone therapy with PARP inhibitors for men with mCRPC and BRCA1, BRCA2, or ATM variants
  107. PARP inhibitors as first-line therapy for men with mCRPC and BRCA1 or BRCA2 variants
  108. PARP inhibitors as first-line therapy for men with mCRPC and variants in homologous recombination repair genes
  109. Certain factors affect prognosis (chance of recovery) and treatment options.
  110. Prostate cancer may recur (come back) after it has been treated.
  111. Treatment Option Overview
  112. Key Points
  113. There are different types of treatment for people with prostate cancer.
  114. The following types of treatment are used:
  115. Watchful waiting or active surveillance
  116. Surgery
  117. Radiation therapy and radiopharmaceutical therapy
  118. Hormone therapy
  119. Chemotherapy
  120. Targeted therapy
  121. Immunotherapy
  122. Bisphosphonate therapy
  123. There are treatments for bone pain caused by bone metastases or hormone therapy.
  124. New types of treatment are being tested in clinical trials.
  125. Cryosurgery
  126. High-intensity focused ultrasound therapy
  127. Proton beam radiation therapy
  128. Photodynamic therapy
  129. Treatment for prostate cancer may cause side effects.
  130. Patients may want to think about taking part in a clinical trial.
  131. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  132. Follow-up care may be needed.
  133. Treatment of Stage I Prostate Cancer
  134. Treatment of Stage II Prostate Cancer
  135. Treatment of Stage III Prostate Cancer
  136. Treatment of Stage IV Prostate Cancer
  137. Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Disease and treatment settings

Casodex: advanced Prostate cancer

Disease and treatment setting

In combination with an LHRH analogue for advanced prostate cancer

CASODEX: metastatic Carcinoma of the Prostate

Disease and treatment setting

INDICATIONS AND USAGE CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate.

Docetaxel: metastatic Prostate cancer

Disease and treatment setting

1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.

DOCIVYX: metastatic Prostate cancer

Disease and treatment setting

1.3 Prostate Cancer DOCIVYX in combination with prednisone is indicated for the treatment of patients with metastatic CRPC.

ELIGARD: advanced Prostate cancer

Disease and treatment setting

ELIGARD ® is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer ( 1 )

ERLEADA: metastatic Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor...

FIRMAGON: advanced Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer.

Jevtana: metastatic Prostate cancer

Disease and treatment setting

JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

LEUPROLIDE ACETATE DEPOT: advanced Prostate cancer

Disease and treatment setting

INDICATIONS AND USAGE LEUPROLIDE ACETATE FOR DEPOT SUSPENSION 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer.

Lupron Depot: advanced Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration (leuprolide acetate) are indicated for the treatment of...

LUTRATE DEPOT: advanced Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE LUTRATE DEPOT 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer.

Lynparza: metastatic Prostate cancer after prior therapy

Disease and treatment setting

1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR)...

Lynparza: metastatic Prostate cancer with BRCA stated without a specific alteration

Disease and treatment setting

1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the...

NUBEQA: metastatic Prostate cancer

Disease and treatment setting

( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

Orgovyx: advanced Prostate cancer

Disease and treatment setting

ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer ( 1 ).

PLUVICTO: metastatic Prostate cancer

Disease and treatment setting

1.1 Metastatic Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer PLUVICTO is indicated in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of adult patients with prostate-specific...

PLUVICTO: metastatic Prostate cancer after prior therapy

Disease and treatment setting

( 1.1 ) Metastatic Androgen Pathway Modulation-Resistant (mAPMR) Prostate Cancer for the treatment of adult patients with PSMA-positive metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer who have been treated with...

Prostate Cancer

Disease and treatment setting

Prostate Cancer

PROVENGE: metastatic Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE PROVENGE ® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

recurrent Prostate Cancer

Disease and treatment setting

Treatment of Recurrent Hormone-Sensitive or Hormone-Resistant Prostate Cancer

Rubraca: metastatic Prostate cancer with BRCA mutation after prior therapy

Disease and treatment setting

Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based...

Rubraca: metastatic Prostate cancer with BRCA mutation after prior therapy

Disease and treatment setting

( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen...

Rubraca: metastatic Prostate cancer with BRCA stated without a specific alteration, BRCA mutation after prior therapy

Disease and treatment setting

1.2 BRCA -mutated Metastatic Castration-Resistant Prostate Cancer RUBRACA is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate...

Stage I Prostate Cancer

Disease and treatment setting

Treatment of Stage I Prostate Cancer

Stage II Prostate Cancer

Disease and treatment setting

Treatment of Stage II Prostate Cancer

Stage III Prostate Cancer

Disease and treatment setting

Treatment of Stage III Prostate Cancer

Stage IV Prostate Cancer

Disease and treatment setting

Treatment of Stage IV Prostate Cancer

Talzenna: metastatic Prostate cancer

Disease and treatment setting

1.2 HRR Gene-mutated mCRPC TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) [see...

Trelstar: advanced Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ].

TRUQAP: metastatic Prostate cancer

Disease and treatment setting

1.2 PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer TRUQAP, in combination with abiraterone and prednisone, is indicated for treatment of adult patients with metastatic androgen pathway...

Vabrinty: advanced Prostate cancer

Disease and treatment setting

VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.

Xofigo: metastatic Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

Xtandi: metastatic Prostate cancer

Disease and treatment setting

• non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with:

YONSA: metastatic Prostate cancer

Disease and treatment setting

YONSA is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC).

ZOLADEX: advanced Carcinoma of the Prostate

Disease and treatment setting

1 INDICATIONS AND USAGE ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Use as palliative treatment of...

Zytiga: metastatic Prostate cancer

Disease and treatment setting

1 INDICATIONS AND USAGE ZYTIGA is indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) ZYTIGA...

Drug labels

ABIRATERONE ACETATE

Label date 2026-06-16

Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with...

DailyMed label

AKEEGA

Label date 2025-12-18

AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA2 -mutated ( BRCA2 m) metastatic castration-sensitive prostate cancer (mCSPC). AKEEGA with prednisone is indicated for...

DailyMed label

Axumin

Label date 2025-03-05

Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. Axumin is a radioactive diagnostic...

DailyMed label

Bicalutamide

Label date 2026-04-23

1. INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate....

DailyMed label

Bicalutamide

Label date 2026-02-27

1. INDICATIONS AND USAGE Bicalutamide tablets 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate....

DailyMed label

BILDYOS

Label date 2026-08-18

Bildyos is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) of...

DailyMed label

Boncresa

Label date 2025-12-22

Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of...

DailyMed label

BOSAYA

Label date 2026-03-27

Bosaya is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

CAMCEVI

Label date 2026-02-18

CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer. CAMCEVI is a gonadotropin-releasing hormone (GnRH) agonist indicated for the treatment of adult patients with advanced prostate cancer.

DailyMed label

CASODEX

Label date 2026-02-27

1. INDICATIONS AND USAGE CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. CASODEX 150 mg...

DailyMed label

Choline C 11

Label date 2025-12-26

Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging...

DailyMed label

CONEXXENCE

Label date 2025-12-15

Conexxence is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

Denosumab-BMWO

Label date 2026-02-05

Denosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

ELIGARD

Label date 2019-04-29

ELIGARD ® is indicated for the palliative treatment of advanced prostate cancer. ELIGARD ® is a gonadotropin releasing hormone (GnRH) agonist indicated for the palliative treatment of advanced prostate cancer ( 1 )

DailyMed label

Eligard

Label date 2026-04-30

ELIGARD is indicated for the treatment of advanced prostate cancer. ELIGARD is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )

DailyMed label

ENOBY

Label date 2026-01-16

Enoby is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

ERLEADA

Label date 2026-07-02

ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the...

DailyMed label

FIRMAGON

Label date 2024-01-30

FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer. FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. ( 1 )

DailyMed label

Gallium Ga-68 PSMA-11

Label date 2025-01-01

Gallium Ga 68 Gozetotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial...

DailyMed label

Gallium Ga-68 PSMA-11

Label date 2025-11-14

Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial...

DailyMed label

Gozellix

Label date 2025-04-11

GOZELLIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for...

DailyMed label

ILLUCCIX

Label date 2026-06-15

ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for...

DailyMed label

Jalyn

Label date 2026-03-09

JALYN is a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1...

DailyMed label

Jevtana

Label date 2025-10-07

JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule...

DailyMed label

JUBBONTI

Label date 2025-10-30

Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of...

DailyMed label

LEUPROLIDE ACETATE DEPOT

Label date 2024-08-27

1. INDICATIONS AND USAGE LEUPROLIDE ACETATE FOR DEPOT SUSPENSION 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer. LEUPROLIDE ACETATE FOR DEPOT SUSPENSION is a...

DailyMed label

LOCAMETZ

Label date 2026-01-15

LOCAMETZ, after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates...

DailyMed label

Lupron Depot

Label date 2026-03-15

LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration (leuprolide acetate) are indicated for the treatment of advanced prostate cancer....

DailyMed label

LUTRATE DEPOT

Label date 2025-06-03

LUTRATE DEPOT 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer. LUTRATE DEPOT is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Treatment of advanced prostate...

DailyMed label

NUBEQA

Label date 2025-06-03

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic...

DailyMed label

Orgovyx

Label date 2025-10-10

ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer (...

DailyMed label

OSPOMYV

Label date 2025-11-11

Ospomyv is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

OSVYRTI

Label date 2026-07-07

OSVYRTI is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

PLUVICTO

Label date 2026-08-12

PLUVICTO is a radioligand therapeutic agent indicated: Metastatic Androgen Pathway Modulation-Naïve or -Sensitive (mAPMN/S) Prostate Cancer in combination with androgen receptor pathway inhibitor (ARPI) therapy for the treatment of...

DailyMed label

POSLUMA

Label date 2026-07-25

POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with...

DailyMed label

Prolia

Label date 2026-06-26

Prolia is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

PROSCAR

Label date 2026-03-18

PROSCAR, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): Improve symptoms Reduce the risk of acute urinary retention Reduce the risk...

DailyMed label

PROVENGE

Label date 2025-10-03

PROVENGE ® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer. PROVENGE is an autologous...

DailyMed label

PYLARIFY

Label date 2026-02-18

PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with...

DailyMed label

PYLARIFY TRUVU

Label date 2026-07-01

PYLARIFY TRUVU is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy...

DailyMed label

Rubraca

Label date 2025-12-31

RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian,...

DailyMed label

Sandostatin LAR Depot

Label date 2025-12-22

SANDOSTATIN LAR DEPOT 10 mg, 20 mg, and 30 mg is indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated. SANDOSTATIN LAR DEPOT is a somatostatin analogue indicated for:...

DailyMed label

Stoboclo

Label date 2026-02-05

Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1.1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1.2 ) of...

DailyMed label

Trelstar

Label date 2026-06-30

TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. TRELSTAR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )

DailyMed label

TRUQAP

Label date 2026-06-12

TRUQAP is a kinase inhibitor indicated: HR positive, HER2 negative locally advanced or metastatic breast cancer • in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal...

DailyMed label

Vabrinty

Label date 2026-04-30

VABRINTY is indicated for the treatment of advanced prostate cancer. VABRINTY is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer. ( 1 )

DailyMed label

Xofigo

Label date 2026-03-02

Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. Xofigo is an alpha particle-emitting radioactive therapeutic agent...

DailyMed label

Xtandi

Label date 2026-07-28

XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with...

DailyMed label

YONSA

Label date 2026-06-08

YONSA is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. YONSA is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment...

DailyMed label

ZOLADEX

Label date 2026-03-24

ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Use as palliative treatment of advanced carcinoma of...

DailyMed label

zoledronic acid

Label date 2025-03-11

Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. ( 1.1 ) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with...

DailyMed label

zoledronic acid

Label date 2021-09-20

Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. ( 1.1 ) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with...

DailyMed label

Zytiga

Label date 2025-03-28

ZYTIGA is indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) ZYTIGA is a CYP17 inhibitor...

DailyMed label